European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Trends & Forecast to 2017

News provided by

Oct 22, 2013, 07:30 ET

NEW YORK, Oct. 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017
http://www.reportlinker.com/p01158259/European-Nuclear-Medicine/Radiopharmaceuticals--Stable-Isotopes-Market-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-Radiation-Therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Deuterium-C-13-–-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

The radiopharmaceuticals market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 83% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by Thallium–201(Tl-201), Gallium–67 (Ga-67) and Iodine-123 (I-123). SPECT is majorly used in cardiology related diagnosis; it is poised to grow at a CAGR of 7.0% from 2012 to 2017. The PET radioisotopes market is dominated by Fluoride-18 (F-18), followed by Rubidium-82 (Rb-82).

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters is not arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by Iodine–131(I-131), which is poised to grow at a CAGR of 3.9% from 2012 to 2017. European market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin's lymphoma. Significant isotopes in the brachytherapy market are Cesium-131 (Cs-131), Iodine-125 (I-125), Palladium-103 (Pd-103), and Iridium-192 (Ir-192). German is the major market for brachytherapy in terms of market share, followed by France. However, this market is showing slow growth due to reimbursement issues.

European stable isotopes market is dominated by Deuterium (D2), Oxygen-18 (O-18), Carbon-13 (C-13), and Nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The European stable isotopes market was estimated at $24.7 million in 2012 and expected to reach $37.7 million by 2017 at a CAGR of 8.8%.

Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are boosting up the European nuclear medicines market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential in the clinical diagnosis and therapeutic applications while the shutdown of NRU in 2016 and OSIRIS in France by 2018 seems to be the major threat for the manufacturers.

Germany is the largest consumer market for radiopharmaceuticals in the Europe. There are only 5 major reactors in the world and the rest of the countries are completely depend on the productions form those reactors and a few countries such as Poland, Australia, Argentina, and South Africa have started producing Mo-99 at their own reactors.

Major players in the radiopharmaceuticals market are Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany). The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.), and Sigma Aldrich (U.S.) - in 2012; they jointly contributed more than 50% to the European revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Germany, France, Italy, Spain, U.K., Russia, and Rest of Europe) to provide in-depth information on the European scenario.

European Radiopharmaceuticals Market

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others
Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90
Lu-177
Others
Alpha emitters
Brachytherapy
Cs-131
I-125
Pd-103
Ir-192
Others

European Enriched Stable Isotopes Market

Deuterium
Oxygen-18
Carbon-13
Nitrogen-15
Others

Radiopharmaceutical and Stable Isotope Markets, By Country

France
Germany
Italy
Spain
U.K.
Russia
RoE

Customer Interested in this report also can view

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

1 INTRODUCTION 25

1.1 KEY TAKE-AWAYS 25
1.2 REPORT DESCRIPTION 25
1.3 MARKETS COVERED 27
1.4 STAKEHOLDERS 28
1.5 RESEARCH METHODOLOGY 29
1.5.1 MARKET SIZE 29
1.5.2 MARKET SHARE 30
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 30
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 30
1.5.5 ASSUMPTIONS 31

2 EXECUTIVE SUMMARY 32

3 MARKET OVERVIEW 37

3.1 INTRODUCTION 38
3.2 DEFINITION OF RADIOPHARMACEUTICALS 38
3.3 EVOLUTION 39
3.4 MARKET SEGMENTATION 40
3.4.1 RADIOPHARMACEUTICALS 40
3.4.2 STABLE ISOTOPES 41
3.5 MARKET DYNAMICS 42
3.5.1 DRIVERS 43
3.5.1.1 Increasing incidence of cancer and cardiac ailments boosts the demand for radiopharmaceuticals 43
3.5.1.2 Increasing use of SPECT and PET scans results in rise of radiopharmaceutical usage 43
3.5.1.3 Rising awareness of radiopharmaceuticals to spur growth 44
3.5.1.4 Ready availability of radiopharmaceuticals from cyclotrons to goad the growth 44
3.5.2 RESTRAINTS 44
3.5.2.1 Shorter half-life of radiopharmaceuticals restricts the usage 44
3.5.2.2 High capital to limit the buying of scanners 45
3.5.2.3 Stringent regulatory guidelines and GMP to negatively impact growth 45
3.5.2.4 Competition from conventional diagnostic procedures 46
3.5.3 OPPORTUNITIES 46
3.5.3.1 Potential radioisotopes in the pipeline 46
3.5.3.2 Alpha radioimmunotherapy-based targeted cancer treatment 47
3.5.3.3 Alternative diagnostic radiopharmaceutical solutions 47
3.5.3.4 Cyclotron based production 48

3.5.3.5 Neurological applications 48
3.5.4 THREAT 48
3.5.4.1 Shutdown of nuclear reactors to impact production of radioisotopes 48
3.6 WINNING IMPERATIVES 49
3.6.1 INVESTMENTS ON NEW RADIOISOTOPES AND NOVEL APPLICATIONS 49
3.6.2 SHIFT TOWARDS LEU-BASED MO-99 PRODUCTION 49
3.7 BURNING ISSUES 50
3.7.1 HIGH COST OF PET CAMERAS 50
3.7.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M 50
3.8 REGULATORY AFFAIRS 51
3.8.1 GERMANY 51
3.8.1.1 German Medicinal Products Act (AMG) 51
3.8.1.2 Amendments to the German Medicinal Products Act (AMG) 52
3.8.2 FRANCE 52
3.8.2.1 Agence Française de la Securité Sanitaire des Produits de la Santé (AFSSAPS) 52
3.8.3 U.K. 53
3.8.3.1 The Medicines and Healthcare Products Regulatory Agency (MHRA) 53
3.8.4 SPAIN 53
3.8.5 ITALY 54
3.8.5.1 The Italian Pharmaceutical Agency (AIFA) 54
3.8.6 RUSSIA 54
3.8.6.1 The Federal Law 54
3.9 MARKET SHARE ANALYSIS 55
3.9.1 RADIOPHARMACEUTICALS MARKET 55
3.9.2 ENRICHED STABLE ISOTOPE MARKET 57

4 EUROPEAN RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 58

4.1 INTRODUCTION 59
4.2 DIAGNOSTIC MARKET 59
4.2.1 OPPORTUNITY MATRIX 60
4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) RADIOPHARMACEUTICALS 62
4.2.2.1 Technetium-99m (Tc-99m) 64
4.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes 66
4.2.2.1.2 Factors affecting Technetium-99m market 68
4.2.2.1.2.1 Technetium can combine with 31 different carrier molecules 68
4.2.2.1.2.2 Lack of availability of technetium 68
4.2.2.2 Thallium-201 (Tl-201) 68
4.2.2.2.1 Tl-201 is a potential substitute for Tc-99m 69
4.2.2.3 Gallium-67 (Ga-67) 70
4.2.2.3.1 Fluorine-18 (PET) might seize Ga-67 (SPECT) market share in the near future 70
4.2.2.4 Iodine (I-123) 71
4.2.2.5 Others 73
4.2.3 POSITRON-EMISSION TOMOGRAPHY (PET) RADIOPHARMACEUTICALS 75
4.2.3.1 Fluorine-18 77
4.2.3.1.1 FDG 77
4.2.3.1.2 Florbetapir 78
4.2.3.1.3 Factors affecting Fluorine-18 market 79
4.2.3.1.3.1 Rise in PET procedures increases demand for FDG 79
4.2.3.1.3.2 High generation costs of FDG 80
4.2.3.1.3.3 Need for speedy & efficient transportation 80
4.2.3.2 Rubidium-82 (Rb-82) 80
4.2.3.3 Others 81
4.3 THERAPEUTIC ISOTOPES 83
4.3.1 OPPORTUNITY MATRIX 84

4.3.2 BETA EMITTERS 85
4.3.2.1 Iodine-131 (I-131) 87
4.3.2.2 Yttrium-90 (Y-90) 89
4.3.2.2.1 Y-90 market influenced by popularity of Nordion's TheraSphere 89
4.3.2.3 Samarium-153 (Sm-153) 90
4.3.2.4 Rhenium-186 (Re-186) 92
4.3.2.5 Lutetium-177 (Lu-177) 93
4.3.2.5.1 Lu-177 is a potential treatment option for neuroendocrine cancer 94
4.3.2.6 Others 95
4.3.2.6.1 Re-188 and P-33 are notable promising isotope 95
4.3.3 ALPHA EMITTERS 96
4.3.3.1 Radium-223 (Ra-223) & Alpharadin 97
4.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC 99
4.3.3.1.2 First in-class alpha pharmaceutical 99
4.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy 99
4.3.3.1.4 Success of Alpharadin 100
4.3.3.1.5 Porter's five forces analysis 100
4.3.3.1.6 SWOT analysis 102
4.3.3.2 Actinium-225 (Ac-225) 103
4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212) 103
4.3.3.4 Astatine-211 (At-211) 103
4.3.3.5 Radium-224 (Ra-224) 103
4.3.3.6 Thorium-227 (Th-227) 104
4.3.4 BRACHYTHERAPY 104
4.3.4.1 Cesium-131 108
4.3.4.2 Iodine-125 109
4.3.4.3 Palladium-103 110
4.3.4.4 Iridium-192 111
4.3.4.5 Others 112

5 EUROPEAN RADIOPHARMACEUTICALS MARKET,
BY APPLICATION/INDICATION 114

5.1 INTRODUCTION 115
5.2 DIAGNOSTIC APPLICATION 115
5.2.1 SPECT 116
5.2.1.1 Cardiology 118
5.2.1.2 Lymphoma 119
5.2.1.3 Thyroid 120
5.2.1.4 Neurology 122
5.2.1.4.1 Alzheimer's, dementia, and Parkinson's disease driving growth of the neurology SPECT market 122
5.2.1.5 Others 123
5.2.2 PET 124
5.2.2.1 Oncology 125
5.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan 126
5.2.2.2 Cardiology 127
5.2.2.3 Neurology 128
5.2.2.4 Others 129
5.3 THERAPEUTIC APPLICATION 131
5.3.1 THYROID 132
5.3.2 BONE METASTASIS 134
5.3.3 LYMPHOMA 135
5.3.4 ENDOCRINE TUMORS 136
5.3.5 OTHERS 138

6 EUROPEAN ENRICHED STABLE ISOTOPES MARKET 139

6.1 INTRODUCTION 140
6.2 MARKET OVERVIEW 141
6.3 MARKET DYNAMICS 142
6.3.1 DRIVERS 142
6.3.1.1 Stable isotopes are natural in origin & hence safe 142
6.3.1.2 Proteomics & system biology, major factors to boost the growth of stables 142
6.3.1.3 Medical applications propel stable isotopes market growth 142
6.3.2 RESTRAINTS 143
6.3.2.1 Harmful effects of high doses of stable isotopes affect market growth 143
6.3.2.2 High cost of stables isotope 143
6.4 ENRICHED STABLES MARKET, BY ISOTOPE 144
6.4.1 DEUTERIUM & O-18 ARE PROMISING ISOTOPES 145
6.4.2 CARBON-13 147
6.4.3 DEUTERIUM 148
6.4.4 OXYGEN-18 149
6.4.5 NITROGEN-15 150
6.4.6 OTHER STABLE ISOTOPES 151
6.5 ENRICHED STABLES MARKET, BY APPLICATION 152
6.5.1 DIAGNOSTIC & THERAPY 152
6.5.2 RESEARCH 154
6.5.3 PHARMACEUTICAL 155
6.5.4 INDUSTRIAL SECTOR 156

7 GEOGRAPHIC ANALYSIS 158

7.1 INTRODUCTION 158
7.2 GERMANY 159
7.3 FRANCE 165
7.4 U.K. 170
7.5 SPAIN 175
7.6 ITALY 180
7.7 RUSSIA 185
7.8 REST OF EUROPE 190

8 COMPETITIVE LANDSCAPE 196

8.1 INTRODUCTION 196
8.2 MERGERS & ACQUISITIONS 197
8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES 198
8.4 NEW PRODUCTS LAUNCH 201
8.5 EXPANSIONS 203
8.6 OTHER DEVELOPMENTS 204

9 COMPANY PROFILES 208
(Overview, Financials, Products & Services, Strategy, & Developments)*

9.1 COMPANIES 208
9.1.1 BRACCO IMAGING S.P.A. 208
9.1.2 CAMBRIDGE ISOTOPE LABORATORIES, INC. 211
9.1.3 CARDINAL HEALTH, INC. 215
9.1.4 COVIDIEN, PLC 221
9.1.5 ECZACIBASI-MONROL 226
9.1.6 FUJIFILM HOLDINGS CORPORATION 228
9.1.7 GE HEALTHCARE (SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 233
9.1.8 IBA GROUP 239
9.1.9 ISOTEC, INC. (SIGMA-ALDRICH) 246
9.1.10 LANTHEUS MEDICAL IMAGING, INC. 250
9.1.11 NORDION, INC. 257
9.1.12 NTP RADIOISOTOPES (PTY), LTD. 264
9.1.13 PETNET SOLUTIONS, INC. (A SUBSIDIARY OF SIEMENS MEDICAL SOLUTIONS USA, INC.) 267
9.1.14 TAIYO NIPPON SANSO CORPORATION 272
9.1.15 ROTEM INDUSTRIES, LTD., INC. 276
9.1.16 URENCO LIMITED 278
9.2 INSTITUTES 282
9.2.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 282
9.2.2 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE 285
9.2.3 INSTITUTE OF ISOTOPES CO., LTD. 287
9.2.4 INSTITUTE OF RADIOELEMENT (IRE) 290
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 33
TABLE 2 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 60
TABLE 3 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 63
TABLE 4 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 64
TABLE 5 INDICATIONS DIAGNOSED BY TC-99M 65
TABLE 6 EUROPE: TC-99M MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 67
TABLE 7 EUROPE: TL-201 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 69
TABLE 8 EUROPE: GA-67 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 71
TABLE 9 EUROPE: I-123 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 72
TABLE 10 EUROPE: OTHER RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 74
TABLE 11 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 76
TABLE 12 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 77
TABLE 13 EUROPE: F-18 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79
TABLE 14 EUROPE: RB-82 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 81
TABLE 15 EUROPE: OTHER PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 82
TABLE 16 EUROPE: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 83
TABLE 17 EUROPE: BETA EMITTER RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 86

TABLE 18 EUROPE: BETA EMITTER RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 87
TABLE 19 EUROPE: I-131 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 88
TABLE 20 EUROPE: Y-90 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 90
TABLE 21 EUROPE: SM-153 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 91
TABLE 22 EUROPE: RE-186 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 93
TABLE 23 EUROPE: LU-177 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 94
TABLE 24 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 96
TABLE 25 ALPHA EMITTERS VS BETA EMITTERS 97
TABLE 26 RADIOPHARMACEUTICALS CHARACTERISTICS & DOSE DELIVERY OVER TIME 105
TABLE 27 EUROPE: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 107
TABLE 28 EUROPE: BRACHYTHERAPY MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 108
TABLE 29 EUROPE: CS-131 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 109
TABLE 30 EUROPE: I-125 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 110
TABLE 31 EUROPE: PD-103 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 111
TABLE 32 EUROPE: IR-192 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 112

TABLE 33 EUROPE: OTHER BRACHYTHERAPY MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 113
TABLE 34 EUROPE: SPECT APPLICATION MARKET, 2010 – 2017 ($MILLION) 117
TABLE 35 EUROPE: CARDIOLOGY SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 118
TABLE 36 EUROPE: LYMPHOMA SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 120
TABLE 37 EUROPE: THYROID SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 121
TABLE 38 EUROPE: NEUROLOGY SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 123
TABLE 39 EUROPE: OTHER SPECT APPLICATIONS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 124
TABLE 40 EUROPE: PET APPLICATION MARKET, 2010 – 2017 ($MILLION) 125
TABLE 41 EUROPE: ONCOLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 126
TABLE 42 EUROPE: CARDIOLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 127
TABLE 43 EUROPE: NEUROLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 129
TABLE 44 EUROPE: OTHER PET APPLICATIONS MARKET, BY COUNTRY,

2010 – 2017 ($MILLION) 130
TABLE 45 EUROPE: RADIOPHARMACEUTICAL THERAPEUTIC APPLICATION MARKET, 2010 – 2017 ($MILLION) 131
TABLE 46 EUROPE: RADIOPHARMACEUTICAL THERAPEUTIC APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 132
TABLE 47 EUROPE: RADIOPHARMACEUTICAL THYROID APPLICATION MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 133
TABLE 48 EUROPE: RADIOPHARMACEUTICAL BONE METASTASIS APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 135
TABLE 49 EUROPE: RADIOPHARMACEUTICAL LYMPHOMA APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 136
TABLE 50 EUROPE: RADIOPHARMACEUTICAL ENDOCRINE APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 137
TABLE 51 EUROPE: RADIOPHARMACEUTICAL OTHER APPLICATIONS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 138
TABLE 52 EUROPE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 144
TABLE 53 EUROPE: STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 146

TABLE 54 EUROPE: CARBON STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 147
TABLE 55 EUROPE: DEUTERIUM STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 148
TABLE 56 EUROPE: OXYGEN STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 149
TABLE 57 EUROPE: NITROGEN STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 150
TABLE 58 EUROPE: OTHER STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 151
TABLE 59 EUROPE: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 152
TABLE 60 EUROPE: STABLE ISOTOPES MARKET FOR DIAGNOSTIC & THERAPEUTIC APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 153
TABLE 61 EUROPE: STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 155
TABLE 62 EUROPE: STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 156
TABLE 63 EUROPE: STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 157
TABLE 64 GERMANY: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 161
TABLE 65 GERMANY: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 162
TABLE 66 GERMANY: RADIOPHARMACEUTICAL MARKET, BY THERAPY,|
2010 – 2017 ($MILLION) 162
TABLE 67 GERMANY: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 163

TABLE 68 GERMANY: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 164
TABLE 69 GERMANY: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 165
TABLE 70 FRANCE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 166
TABLE 71 FRANCE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 167
TABLE 72 FRANCE: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 167
TABLE 73 FRANCE: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 168
TABLE 74 FRANCE: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 169
TABLE 75 FRANCE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 170
TABLE 76 U.K.: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 171
TABLE 77 U.K.: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 172
TABLE 78 U.K.: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 172

TABLE 79 U.K.: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 173
TABLE 80 U.K.: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 174
TABLE 81 U.K.: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 175
TABLE 82 SPAIN: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 176
TABLE 83 SPAIN: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 177
TABLE 84 SPAIN: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 177
TABLE 85 SPAIN: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 178
TABLE 86 SPAIN: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 179
TABLE 87 SPAIN: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 180
TABLE 88 ITALY: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 181
TABLE 89 ITALY: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 182
TABLE 90 ITALY: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 182
TABLE 91 ITALY: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 183
TABLE 92 ITALY: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 184

TABLE 93 ITALY: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 185
TABLE 94 RUSSIA: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 186
TABLE 95 RUSSIA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 187
TABLE 96 RUSSIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 187
TABLE 97 RUSSIA: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 188
TABLE 98 RUSSIA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 189
TABLE 99 RUSSIA: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 190
TABLE 100 ROE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 191
TABLE 101 ROE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 192
TABLE 102 ROE: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 192
TABLE 103 ROE: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 193
TABLE 104 ROE: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 194
TABLE 105 ROE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 195
TABLE 106 MERGERS & ACQUISITIONS, 2010 – 2012 197
TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES, 2010 – 2013 198
TABLE 108 NEW PRODUCTS LAUNCH, 2010 –2013 201
TABLE 109 EXPANSIONS, 2010 –2012 203

TABLE 110 OTHER DEVELOPMENTS, 2010 – 2012 204
TABLE 111 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY SEGMENT, 2010 – 2012 ($MILLION) 212
TABLE 112 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY GEOGRAPHY, 2010 – 2012 ($MILLION) 213
TABLE 113 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 216
TABLE 114 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 217
TABLE 115 COVIDIEN, PLC: TOTAL REVENUE AND R&D EXPENDITURE,
2010 – 2012 ($MILLION) 222
TABLE 116 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 222
TABLE 117 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 224
TABLE 118 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 230
TABLE 119 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 230
TABLE 120 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT,
2009 – 2011 ($BILLION) 234
TABLE 121 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($BILLION) 235
TABLE 122 IBA GROUP: MARKET REVENUE, BY SEGMENT,
2009 – 2011 ($MILLION) 240
TABLE 123 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 241
TABLE 124 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 247
TABLE 125 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 248
TABLE 126 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 252
TABLE 127 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 252
TABLE 128 NORDION, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 259
TABLE 129 NORDION, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2017 259
TABLE 130 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES,
2010 – 2012 ($MILLION) 268
TABLE 131 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 268
TABLE 132 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 269
TABLE 133 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 274

LIST OF FIGURES

FIGURE 1 EUROPE: RADIOPHARMACEUTICALS MARKET, BY SEGMENT,
2010 – 2017 33
FIGURE 2 EUROPE: RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2012 ($MILLION) 34
FIGURE 3 EUROPE: STABLE ISOTOPES MARKET, 2012 – 2017 ($MILLION) 36
FIGURE 4 EVOLUTION OF RADIOPHARMACEUTICALS 39
FIGURE 5 RADIOPHARMACEUTICALS MARKET SEGMENTATION 40
FIGURE 6 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION 41
FIGURE 7 MARKET DYNAMICS 42
FIGURE 8 EUROPEAN RADIOPHARMACEUTICALS: MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2012 55
FIGURE 9 EUROPEAN ENRICHED STABLE ISOTOPE: MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2012 57
FIGURE 10 OPPORTUNITY MATRIX: EUROPEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET (2012) 61
FIGURE 11 SPECT RADIOPHARMACEUTICALS MARKET SHARE (2012) 62
FIGURE 12 PET RADIOPHARMACEUTICALS MARKET SHARE(2012) 75
FIGURE 13 OPPORTUNITY MATRIX: EUROPEAN THERAPEUTIC RADIOPHARMACEUTICALS MARKET (2012) 84
FIGURE 14 RA-223 DECAY CHAIN 98
FIGURE 15 PORTER'S FIVE FORCES ANALYSIS FOR ALPHARADIN 101
FIGURE 16 SWOT ANALYSIS OF ALPHARADIN 102
FIGURE 17 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY INDICATION (2012) 116
FIGURE 18 KEY GROWTH STRATEGIES, 2010 –2013 196
FIGURE 19 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION) 212
FIGURE 20 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 – 2012 ($BILLION) 216
FIGURE 21 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE,
2010 – 2012 ($BILLION) 223
FIGURE 22 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 229
FIGURE 23 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION) 234
FIGURE 24 IBA GROUP: TOTAL MARKET REVENUE, 2009 – 2011 ($MILLION) 240
FIGURE 25 ISOTEC INC.: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($BILLION) 247
FIGURE 26 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 251
FIGURE 27 NORDION, INC.: TOTAL MARKET REVENUE, 2010 – 2012 ($BILLION) 258
FIGURE 28 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 273
FIGURE 29 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 – 2011 ($BILLION) 279

To order this report: European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017
http://www.reportlinker.com/p01158259/European-Nuclear-Medicine/Radiopharmaceuticals--Stable-Isotopes-Market-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-Radiation-Therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Deuterium-C-13-–-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker